Download PDF
Semin Neurol 2018; 38(03): 379-391
DOI: 10.1055/s-0038-1660820
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Infection, Immunodeficiency, and Inflammatory Diseases in Autoimmune Neurology

Amanda L. Piquet
1   Department of Neurology, University of Colorado, Aurora, Colorado
,
Stacey L. Clardy
2   Department of Neurology, University of Utah, Salt Lake City, Utah
› Author Affiliations
Further Information

Publication History

Publication Date:
16 July 2018 (online)

    Permissions and Reprints

Abstract

When patients present with neurological syndromes, such as encephalopathy/encephalitis, meningitis, and/or myelopathy/myelitis, the differential diagnosis is often broad, including infectious, inflammatory, autoimmune, vascular, and neoplastic etiologies. Just with inflammatory and autoimmune etiologies alone, there are numerous causative diseases. A comprehensive history and physical examination investigating for extraneurologic manifestations of immune-mediated disease is often necessary. Moreover, evaluating for an underlying infection and/or immunodeficiency becomes a critical aspect to the workup. This article will focus on the association of viral infections and dysregulation of the immune system as triggers of autoimmunity, in addition to various systemic inflammatory diseases that can cause neurological disease either with or without an established rheumatological disorder.

Keywords

autoimmunity - common variable immunodeficiency disease - sarcoidosis - systemic lupus erythematous - Sjögren's syndrome - inflammatory disorder
 

  • References

  • 1 Shapira Y, Agmon-Levin N, Shoenfeld Y. Defining and analyzing geoepidemiology and human autoimmunity. J Autoimmun 2010; 34 (03) J168-J177
    CrossrefPubMedGoogle Scholar
  • 2 Hynson JL, Kornberg AJ, Coleman LT, Shield L, Harvey AS, Kean MJ. Clinical and neuroradiologic features of acute disseminated encephalomyelitis in children. Neurology 2001; 56 (10) 1308-1312
    CrossrefPubMedGoogle Scholar
  • 3 Kipps A, Dick G, Moodie JW. Measles and the central nervous system. Lancet 1983; 2 (8364): 1406-1410
    PubMedGoogle Scholar
  • 4 Karussis D, Petrou P. The spectrum of post-vaccination inflammatory CNS demyelinating syndromes. Autoimmun Rev 2014; 13 (03) 215-224
    CrossrefPubMedGoogle Scholar
  • 5 Armangue T, Leypoldt F, Málaga I. , et al. Herpes simplex virus encephalitis is a trigger of brain autoimmunity. Ann Neurol 2014; 75 (02) 317-323
    CrossrefPubMedGoogle Scholar
  • 6 Linnoila JJ, Binnicker MJ, Majed M, Klein CJ, McKeon A. CSF herpes virus and autoantibody profiles in the evaluation of encephalitis. Neurol Neuroimmunol Neuroinflamm 2016; 3 (04) e245
    CrossrefPubMedGoogle Scholar
  • 7 Schäbitz WR, Rogalewski A, Hagemeister C, Bien CG. VZV brainstem encephalitis triggers NMDA receptor immunoreaction. Neurology 2014; 83 (24) 2309-2311
    CrossrefPubMedGoogle Scholar
  • 8 Getts DR, Chastain EM, Terry RL, Miller SD. Virus infection, antiviral immunity, and autoimmunity. Immunol Rev 2013; 255 (01) 197-209
    CrossrefPubMedGoogle Scholar
  • 9 Ercolini AM, Miller SD. The role of infections in autoimmune disease. Clin Exp Immunol 2009; 155 (01) 1-15
    CrossrefPubMedGoogle Scholar
  • 10 Fujinami RS, Oldstone MB, Wroblewska Z, Frankel ME, Koprowski H. Molecular mimicry in virus infection: cross-reaction of measles virus phosphoprotein or of herpes simplex virus protein with human intermediate filaments. Proc Natl Acad Sci U S A 1983; 80 (08) 2346-2350
    CrossrefPubMedGoogle Scholar
  • 11 Cusick MF, Libbey JE, Fujinami RS. Molecular mimicry as a mechanism of autoimmune disease. Clin Rev Allergy Immunol 2012; 42 (01) 102-111
    CrossrefPubMedGoogle Scholar
  • 12 Kirvan CA, Swedo SE, Heuser JS, Cunningham MW. Mimicry and autoantibody-mediated neuronal cell signaling in Sydenham chorea. Nat Med 2003; 9 (07) 914-920
    CrossrefPubMedGoogle Scholar
  • 13 Ang CW, Jacobs BC, Laman JD. The Guillain-Barré syndrome: a true case of molecular mimicry. Trends Immunol 2004; 25 (02) 61-66
    CrossrefPubMedGoogle Scholar
  • 14 Araujo AQ, Silva MT. The HTLV-1 neurological complex. Lancet Neurol 2006; 5 (12) 1068-1076
    CrossrefPubMedGoogle Scholar
  • 15 Mameli G, Cocco E, Frau J, Marrosu MG, Sechi LA. Epstein Barr Virus and Mycobacterium avium subsp. paratuberculosis peptides are recognized in sera and cerebrospinal fluid of MS patients. Sci Rep 2016; 6: 22401
    CrossrefPubMedGoogle Scholar
  • 16 Husby G, van de Rijn I, Zabriskie JB, Abdin ZH, Williams Jr RC. Antibodies reacting with cytoplasm of subthalamic and caudate nuclei neurons in chorea and acute rheumatic fever. J Exp Med 1976; 144 (04) 1094-1110
    CrossrefPubMedGoogle Scholar
  • 17 Hoffman KL, Hornig M, Yaddanapudi K, Jabado O, Lipkin WI. A murine model for neuropsychiatric disorders associated with group A beta-hemolytic streptococcal infection. J Neurosci 2004; 24 (07) 1780-1791
    CrossrefPubMedGoogle Scholar
  • 18 Bronze MS, Dale JB. Epitopes of streptococcal M proteins that evoke antibodies that cross-react with human brain. J Immunol 1993; 151 (05) 2820-2828
    PubMedGoogle Scholar
  • 19 Jolles S. The variable in common variable immunodeficiency: a disease of complex phenotypes. J Allergy Clin Immunol Pract 2013; 1 (06) 545-556 , quiz 557
    CrossrefPubMedGoogle Scholar
  • 20 Conley ME, Notarangelo LD, Etzioni A. ; Representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies). Diagnostic criteria for primary immunodeficiencies. Clin Immunol 1999; 93 (03) 190-197
    CrossrefPubMedGoogle Scholar
  • 21 Schubert RD, Wilson MR. A tale of two approaches: how metagenomics and proteomics are shaping the future of encephalitis diagnostics. Curr Opin Neurol 2015; 28 (03) 283-287
    CrossrefPubMedGoogle Scholar
  • 22 Wilson MR, Naccache SN, Samayoa E. , et al. Actionable diagnosis of neuroleptospirosis by next-generation sequencing. N Engl J Med 2014; 370 (25) 2408-2417
    CrossrefPubMedGoogle Scholar
  • 23 Quan PL, Wagner TA, Briese T. , et al. Astrovirus encephalitis in boy with X-linked agammaglobulinemia. Emerg Infect Dis 2010; 16 (06) 918-925
    CrossrefPubMedGoogle Scholar
  • 24 Naccache SN, Peggs KS, Mattes FM. , et al. Diagnosis of neuroinvasive astrovirus infection in an immunocompromised adult with encephalitis by unbiased next-generation sequencing. Clin Infect Dis 2015; 60 (06) 919-923
    CrossrefPubMedGoogle Scholar
  • 25 Bonilla FA, Barlan I, Chapel H. , et al. International Consensus Document (ICON): common variable immunodeficiency disorders. J Allergy Clin Immunol Pract 2016; 4 (01) 38-59
    CrossrefPubMedGoogle Scholar
  • 26 Boursiquot JN, Gérard L, Malphettes M. , et al; DEFI Study Group. Granulomatous disease in CVID: retrospective analysis of clinical characteristics and treatment efficacy in a cohort of 59 patients. J Clin Immunol 2013; 33 (01) 84-95
    CrossrefPubMedGoogle Scholar
  • 27 Morimoto Y, Routes JM. Granulomatous disease in common variable immunodeficiency. Curr Allergy Asthma Rep 2005; 5 (05) 370-375
    CrossrefPubMedGoogle Scholar
  • 28 Ardeniz O, Cunningham-Rundles C. Granulomatous disease in common variable immunodeficiency. Clin Immunol 2009; 133 (02) 198-207
    CrossrefPubMedGoogle Scholar
  • 29 Arnold DF, Wiggins J, Cunningham-Rundles C, Misbah SA, Chapel HM. Granulomatous disease: distinguishing primary antibody disease from sarcoidosis. Clin Immunol 2008; 128 (01) 18-22
    CrossrefPubMedGoogle Scholar
  • 30 Misbah SA, Spickett GP, Esiri MM. , et al. Recurrent intra-cranial granulomata presenting as space-occupying lesions in a patient with common variable immunodeficiency. Postgrad Med J 1992; 68 (799) 359-362
    CrossrefPubMedGoogle Scholar
  • 31 Nguyen JT, Green A, Wilson MR, DeRisi JL, Gundling K. Neurologic complications of common variable immunodeficiency. J Clin Immunol 2016; 36 (08) 793-800
    CrossrefPubMedGoogle Scholar
  • 32 Shiboski CH, Shiboski SC, Seror R. , et al; International Sjögren's Syndrome Criteria Working Group. 2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjögren's Syndrome: A consensus and data-driven methodology involving three international patient cohorts. Arthritis Rheumatol 2017; 69 (01) 35-45
    CrossrefPubMedGoogle Scholar
  • 33 Vitali C, Bombardieri S, Jonsson R. , et al; European Study Group on Classification Criteria for Sjögren's Syndrome. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61 (06) 554-558
    CrossrefPubMedGoogle Scholar
  • 34 Delalande S, de Seze J, Fauchais AL. , et al. Neurologic manifestations in primary Sjögren syndrome: a study of 82 patients. Medicine (Baltimore) 2004; 83 (05) 280-291
    CrossrefPubMedGoogle Scholar
  • 35 Ramos-Casals M, Solans R, Rosas J. , et al; GEMESS Study Group. Primary Sjögren syndrome in Spain: clinical and immunologic expression in 1010 patients. Medicine (Baltimore) 2008; 87 (04) 210-219
    CrossrefPubMedGoogle Scholar
  • 36 Kassan SS, Moutsopoulos HM. Clinical manifestations and early diagnosis of Sjögren syndrome. Arch Intern Med 2004; 164 (12) 1275-1284
    CrossrefPubMedGoogle Scholar
  • 37 Morreale M, Marchione P, Giacomini P. , et al. Neurological involvement in primary Sjögren syndrome: a focus on central nervous system. PLoS One 2014; 9 (01) e84605
    CrossrefPubMedGoogle Scholar
  • 38 Valtýsdóttir ST, Gudbjörnsson B, Lindqvist U, Hällgren R, Hetta J. Anxiety and depression in patients with primary Sjögren's syndrome. J Rheumatol 2000; 27 (01) 165-169
    PubMedGoogle Scholar
  • 39 Valtýsdóttir ST, Gudbjörnsson B, Hällgren R, Hetta J. Psychological well-being in patients with primary Sjögren's syndrome. Clin Exp Rheumatol 2000; 18 (05) 597-600
    PubMedGoogle Scholar
  • 40 Tzarouchi LC, Zikou AK, Tsifetaki N. , et al. White matter water diffusion changes in primary Sjögren syndrome. AJNR Am J Neuroradiol 2014; 35 (04) 680-685
    CrossrefPubMedGoogle Scholar
  • 41 Kim SM, Waters P, Vincent A. , et al. Sjogren's syndrome myelopathy: spinal cord involvement in Sjogren's syndrome might be a manifestation of neuromyelitis optica. Mult Scler 2009; 15 (09) 1062-1068
    CrossrefPubMedGoogle Scholar
  • 42 Jarius S, Jacobi C, de Seze J. , et al. Frequency and syndrome specificity of antibodies to aquaporin-4 in neurological patients with rheumatic disorders. Mult Scler 2011; 17 (09) 1067-1073
    CrossrefPubMedGoogle Scholar
  • 43 Jarius S, Wildemann B. AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nat Rev Neurol 2010; 6 (07) 383-392
    CrossrefPubMedGoogle Scholar
  • 44 Tobón GJ, Pers JO, Devauchelle-Pensec V, Youinou P. Neurological disorders in primary Sjögren's syndrome. Autoimmune Dis 2012; 2012: 645967
    PubMedGoogle Scholar
  • 45 Park K, Haberberger RV, Gordon TP, Jackson MW. Antibodies interfering with the type 3 muscarinic receptor pathway inhibit gastrointestinal motility and cholinergic neurotransmission in Sjögren's syndrome. Arthritis Rheum 2011; 63 (05) 1426-1434
    CrossrefPubMedGoogle Scholar
  • 46 Rist S, Sellam J, Hachulla E. , et al; Club Rhumatismes et Inflammation. Experience of intravenous immunoglobulin therapy in neuropathy associated with primary Sjögren's syndrome: a national multicentric retrospective study. Arthritis Care Res (Hoboken) 2011; 63 (09) 1339-1344
    CrossrefPubMedGoogle Scholar
  • 47 Chen WH, Yeh JH, Chiu HC. Plasmapheresis in the treatment of ataxic sensory neuropathy associated with Sjögren's syndrome. Eur Neurol 2001; 45 (04) 270-274
    CrossrefPubMedGoogle Scholar
  • 48 Gottenberg JE, Cinquetti G, Larroche C. , et al; Club Rhumatismes et Inflammations and the French Society of Rheumatology. Efficacy of rituximab in systemic manifestations of primary Sjogren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry. Ann Rheum Dis 2013; 72 (06) 1026-1031
    CrossrefPubMedGoogle Scholar
  • 49 Caroyer JM, Manto MU, Steinfeld SD. Severe sensory neuronopathy responsive to infliximab in primary Sjögren's syndrome. Neurology 2002; 59 (07) 1113-1114
    CrossrefPubMedGoogle Scholar
  • 50 Gottenberg JE, Ravaud P, Puéchal X. , et al. Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome: the JOQUER randomized clinical trial. JAMA 2014; 312 (03) 249-258
    CrossrefPubMedGoogle Scholar
  • 51 Mariette X, Ravaud P, Steinfeld S. , et al. Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS). Arthritis Rheum 2004; 50 (04) 1270-1276
    CrossrefPubMedGoogle Scholar
  • 52 D'Cruz DP, Khamashta MA, Hughes GR. Systemic lupus erythematosus. Lancet 2007; 369 (9561): 587-596
    CrossrefPubMedGoogle Scholar
  • 53 Bhattacharyya S, Helfgott SM. Neurologic complications of systemic lupus erythematosus, Sjögren syndrome, and rheumatoid arthritis. Semin Neurol 2014; 34 (04) 425-436
    Article in Thieme ConnectPubMedGoogle Scholar
  • 54 Cozzani E, Drosera M, Gasparini G, Parodi A. Serology of lupus erythematosus: correlation between immunopathological features and clinical aspects. Autoimmune Dis 2014; 2014: 321359
    PubMedGoogle Scholar
  • 55 Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40 (09) 1725
    CrossrefPubMedGoogle Scholar
  • 56 Devinsky O, Schein A, Najjar S. Epilepsy associated with systemic autoimmune disorders. Epilepsy Curr 2013; 13 (02) 62-68
    CrossrefPubMedGoogle Scholar
  • 57 Appenzeller S, Cendes F, Costallat LT. Epileptic seizures in systemic lupus erythematosus. Neurology 2004; 63 (10) 1808-1812
    CrossrefPubMedGoogle Scholar
  • 58 Timlin H, Petri M. Transient ischemic attack and stroke in systemic lupus erythematosus. Lupus 2013; 22 (12) 1251-1258
    CrossrefPubMedGoogle Scholar
  • 59 Giannakopoulos B, Krilis SA. The pathogenesis of the antiphospholipid syndrome. N Engl J Med 2013; 368 (11) 1033-1044
    CrossrefPubMedGoogle Scholar
  • 60 Hajj-Ali RA, Calabrese LH. Diagnosis and classification of central nervous system vasculitis. J Autoimmun 2014; ;48-49: 149-152
    PubMedGoogle Scholar
  • 61 John S, Hajj-Ali RA. CNS vasculitis. Semin Neurol 2014; 34 (04) 405-412
    Article in Thieme ConnectPubMedGoogle Scholar
  • 62 Chow FC, Marra CM, Cho TA. Cerebrovascular disease in central nervous system infections. Semin Neurol 2011; 31 (03) 286-306
    Article in Thieme ConnectPubMedGoogle Scholar
  • 63 Salvarani C, Brown Jr RD, Huston III J, Morris JM, Hunder GG. Treatment of primary CNS vasculitis with rituximab: case report. Neurology 2014; 82 (14) 1287-1288
    CrossrefPubMedGoogle Scholar
  • 64 Yates M, Watts RA, Bajema IM. , et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis 2016; 75 (09) 1583-1594
    CrossrefPubMedGoogle Scholar
  • 65 Evans J, Steel L, Borg F, Dasgupta B. Long-term efficacy and safety of tocilizumab in giant cell arteritis and large vessel vasculitis. RMD Open 2016; 2 (01) e000137
    CrossrefPubMedGoogle Scholar
  • 66 Devauchelle-Pensec V, Berthelot JM, Cornec D. , et al. Efficacy of first-line tocilizumab therapy in early polymyalgia rheumatica: a prospective longitudinal study. Ann Rheum Dis 2016; 75 (08) 1506-1510
    CrossrefPubMedGoogle Scholar
  • 67 Tavee JO, Stern BJ. Neurosarcoidosis. Clin Chest Med 2015; 36 (04) 643-656
    PubMedGoogle Scholar
  • 68 Allen RK, Sellars RE, Sandstrom PA. A prospective study of 32 patients with neurosarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2003; 20 (02) 118-125
    PubMedGoogle Scholar
  • 69 Gascón-Bayarri J, Mañá J, Martínez-Yélamos S, Murillo O, Reñé R, Rubio F. Neurosarcoidosis: report of 30 cases and a literature survey. Eur J Intern Med 2011; 22 (06) e125-e132
    CrossrefPubMedGoogle Scholar
  • 70 Rybicki BA, Major M, Popovich Jr J, Maliarik MJ, Iannuzzi MC. Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Am J Epidemiol 1997; 145 (03) 234-241
    CrossrefPubMedGoogle Scholar
  • 71 Zajicek JP, Scolding NJ, Foster O. , et al. Central nervous system sarcoidosis--diagnosis and management. QJM 1999; 92 (02) 103-117
    CrossrefPubMedGoogle Scholar
  • 72 Agnihotri SP, Singhal T, Stern BJ, Cho TA. Neurosarcoidosis. Semin Neurol 2014; 34 (04) 386-394
    Article in Thieme ConnectPubMedGoogle Scholar
  • 73 Stern BJ, Krumholz A, Johns C, Scott P, Nissim J. Sarcoidosis and its neurological manifestations. Arch Neurol 1985; 42 (09) 909-917
    CrossrefPubMedGoogle Scholar
  • 74 Chapelon C, Ziza JM, Piette JC. , et al. Neurosarcoidosis: signs, course and treatment in 35 confirmed cases. Medicine (Baltimore) 1990; 69 (05) 261-276
    CrossrefPubMedGoogle Scholar
  • 75 Chow E, Troy SB. The differential diagnosis of hypoglycorrhachia in adult patients. Am J Med Sci 2014; 348 (03) 186-190
    CrossrefPubMedGoogle Scholar
  • 76 Bridel C, Courvoisier DS, Vuilleumier N, Lalive PH. Cerebrospinal fluid angiotensin-converting enzyme for diagnosis of neurosarcoidosis. J Neuroimmunol 2015; 285: 1-3
    CrossrefPubMedGoogle Scholar
  • 77 Nishiyama Y, Yamamoto Y, Fukunaga K. , et al. Comparative evaluation of 18F-FDG PET and 67Ga scintigraphy in patients with sarcoidosis. J Nucl Med 2006; 47 (10) 1571-1576
    PubMedGoogle Scholar
  • 78 Sobic-Saranovic D, Grozdic I, Videnovic-Ivanov J. , et al. The utility of 18F-FDG PET/CT for diagnosis and adjustment of therapy in patients with active chronic sarcoidosis. J Nucl Med 2012; 53 (10) 1543-1549
    CrossrefPubMedGoogle Scholar
  • 79 Sohn M, Culver DA, Judson MA, Scott TF, Tavee J, Nozaki K. Spinal cord neurosarcoidosis. Am J Med Sci 2014; 347 (03) 195-198
    CrossrefPubMedGoogle Scholar
  • 80 Flanagan EP. Autoimmune myelopathies. Handb Clin Neurol 2016; 133: 327-351
    CrossrefPubMedGoogle Scholar
  • 81 Leavitt JA, Campbell RJ. Cost-effectiveness in the diagnosis of sarcoidosis: the conjunctival biopsy. Eye (Lond) 1998; 12 (Pt 6): 959-962
    CrossrefPubMedGoogle Scholar
  • 82 Korkmaz Ekren P, Mogulkoc N, Toreyin ZN. , et al. Conjunctival biopsy as a first choice to confirm a diagnosis of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2016; 33 (03) 196-200
    PubMedGoogle Scholar
  • 83 Pichler MR, Flanagan EP, Aksamit AJ, Leavitt JA, Salomão DR, Keegan BM. Conjunctival biopsy to diagnose neurosarcoidosis in patients with inflammatory nervous system disease of unknown etiology. Neurol Clin Pract 2015; 5 (03) 216-223
    CrossrefPubMedGoogle Scholar
  • 84 Pettersen JA, Zochodne DW, Bell RB, Martin L, Hill MD. Refractory neurosarcoidosis responding to infliximab. Neurology 2002; 59 (10) 1660-1661
    CrossrefPubMedGoogle Scholar
  • 85 O'Reilly MW, Sexton DJ, Dennedy MC. , et al. Radiological remission and recovery of thirst appreciation after infliximab therapy in adipsic diabetes insipidus secondary to neurosarcoidosis. QJM 2015; 108 (08) 657-659
    CrossrefPubMedGoogle Scholar
  • 86 Gelfand JM, Bradshaw MJ, Stern BJ. , et al. Infliximab for the treatment of CNS sarcoidosis: a multi-institutional series. Neurology 2017; 89 (20) 2092-2100
    CrossrefPubMedGoogle Scholar
  • 87 Rossman MD, Newman LS, Baughman RP. , et al. A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2006; 23 (03) 201-208
    PubMedGoogle Scholar
  • 88 Baughman RP, Drent M, Kavuru M. , et al; Sarcoidosis Investigators. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 2006; 174 (07) 795-802
    CrossrefPubMedGoogle Scholar
  • 89 Bomprezzi R, Pati S, Chansakul C, Vollmer T. A case of neurosarcoidosis successfully treated with rituximab. Neurology 2010; 75 (06) 568-570
    CrossrefPubMedGoogle Scholar
  • 90 Hamano H, Kawa S, Horiuchi A. , et al. High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med 2001; 344 (10) 732-738
    CrossrefPubMedGoogle Scholar
  • 91 Stone JH. IgG4-related disease: nomenclature, clinical features, and treatment. Semin Diagn Pathol 2012; 29 (04) 177-190
    CrossrefPubMedGoogle Scholar
  • 92 Carruthers MN, Khosroshahi A, Augustin T, Deshpande V, Stone JH. The diagnostic utility of serum IgG4 concentrations in IgG4-related disease. Ann Rheum Dis 2015; 74 (01) 14-18
    CrossrefPubMedGoogle Scholar
  • 93 Carruthers R, Carruthers M, Della-Torre E. IgG4-related disease and other causes of inflammatory meningeal disease. Semin Neurol 2014; 34 (04) 395-404
    Article in Thieme ConnectPubMedGoogle Scholar
  • 94 Deshpande V, Zen Y, Chan JK. , et al. Consensus statement on the pathology of IgG4-related disease. Mod Pathol 2012; 25 (09) 1181-1192
    CrossrefPubMedGoogle Scholar
  • 95 Lindstrom KM, Cousar JB, Lopes MB. IgG4-related meningeal disease: clinico-pathological features and proposal for diagnostic criteria. Acta Neuropathol 2010; 120 (06) 765-776
    CrossrefPubMedGoogle Scholar
  • 96 Carruthers MN, Topazian MD, Khosroshahi A. , et al. Rituximab for IgG4-related disease: a prospective, open-label trial. Ann Rheum Dis 2015; 74 (06) 1171-1177
    PubMedGoogle Scholar
  • 97 Miller JJ, Venna N, Siva A. Neuro-Behçet disease and autoinflammatory disorders. Semin Neurol 2014; 34 (04) 437-443
    Article in Thieme ConnectPubMedGoogle Scholar
  • 98 Jubelt B, Mihai C, Li TM, Veerapaneni P. Rhombencephalitis / brainstem encephalitis. Curr Neurol Neurosci Rep 2011; 11 (06) 543-552
    CrossrefPubMedGoogle Scholar
  • 99 Maldini C, Lavalley MP, Cheminant M, de Menthon M, Mahr A. Relationships of HLA-B51 or B5 genotype with Behcet's disease clinical characteristics: systematic review and meta-analyses of observational studies. Rheumatology (Oxford) 2012; 51 (05) 887-900
    CrossrefPubMedGoogle Scholar
  • 100 International Team for the Revision of the International Criteria for Behçet's Disease (ITR-ICBD). The International Criteria for Behçet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol 2014; 28 (03) 338-347
    CrossrefPubMedGoogle Scholar
  • 101 Kalra S, Silman A, Akman-Demir G. , et al. Diagnosis and management of Neuro-Behçet's disease: international consensus recommendations. J Neurol 2014; 261 (09) 1662-1676
    CrossrefPubMedGoogle Scholar
  • 102 Moorthy RS, Inomata H, Rao NA. Vogt-Koyanagi-Harada syndrome. Surv Ophthalmol 1995; 39 (04) 265-292
    CrossrefPubMedGoogle Scholar
  • 103 Lavezzo MM, Sakata VM, Morita C. , et al. Vogt-Koyanagi-Harada disease: review of a rare autoimmune disease targeting antigens of melanocytes. Orphanet J Rare Dis 2016; 11: 29
    CrossrefPubMedGoogle Scholar
  • 104 Greco A, Fusconi M, Gallo A. , et al. Vogt-Koyanagi-Harada syndrome. Autoimmun Rev 2013; 12 (11) 1033-1038
    CrossrefPubMedGoogle Scholar
  • 105 Levy-Clarke G, Jabs DA, Read RW, Rosenbaum JT, Vitale A, Van Gelder RN. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology 2014; 121 (03) 785-96.e3
    CrossrefPubMedGoogle Scholar
  • 106 Flores-Robles BJ, Blanco-Madrigal J, Sanabria-Sanchinel AA, Pascual DH, Demetrio-Pablo R, Blanco R. Anti-TNFα therapy and switching in severe uveitis related to Vogt-Koyanagi-Harada syndrome. Eur J Rheumatol 2017; 4 (03) 226-228
    CrossrefPubMedGoogle Scholar
  • 107 Cuchacovich M, Solanes F, Díaz G. , et al. Comparison of the clinical efficacy of two different immunosuppressive regimens in patients with chronic Vogt-Koyanagi-Harada disease. Ocul Immunol Inflamm 2010; 18 (03) 200-207
    CrossrefPubMedGoogle Scholar